AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WILMINGTON, Del.--( BUSINESS WIRE )--AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), December 6-10, 2022.

AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022

Bristol-Myers

Both have outperformed the stock market this year.

2 Stocks to Buy Whether or Not a Recession Is Coming

The CHMP recommends expanded use of AstraZeneca's (AZN) three key cancer drugs, Lynparza, Enhertu and Imfinzi.

AstraZeneca's (AZN) 3 Cancer Drugs Get CHMP Nod for Expanded Use

AstraZeneca (AZN) gets its second FDA approval for the Imfinzi+Imjudo combo in non-small cell lung cancer (NSCLC) indication.

AstraZeneca's (AZN) Imfinzi/Imjudo Combo Gets Another FDA Nod

TOKYO & MUNICH--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Advanced Gastric Cancer

The company trounced analyst profitability estimates for its latest quarter and raised its guidance.

Why AstraZeneca Stock Shot Higher Today

AstraZeneca PLC (NASDAQ:AZN ) Q3 2022 Earnings Conference Call November 10, 2022 6:45 AM ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO David Fredrickson - Executive Vice-President of Oncology Business Unit Susan Galbraith - EVP of Oncology Research & Development Ruud Dobber - Executive Vice-President of BioPharmaceuticals Business Unit Menelas Pangalos - EVP of BioPharmaceuticals R&D Marc Dunoyer - CEO of Alexion Leon Wang - EVP of International & China President Iskra Reic - EVP, Vaccines and Immune Therapies Conference Call Participants Simon Baker - Redburn Sachin Jain - BofA Securities Andrew Baum - Citi Timothy Anderson - Wolfe Research Mark Purcell - Morgan Stanley Stephen Scala - Cowen and Company James Gordon - JPMorgan Richard Parkes - BNP Paribas Exane Eric Le Berrigaud - Stifel Michael Leuchten - UBS Jo Walton - Credit Suisse Emmanuel Papadakis - Deutsche Bank Seamus Fernandez - Guggenheim Peter Welford - Jefferies Adam Karlsson - ABG Sundal Collier Luisa Hector - Berenberg Operator Good morning to those joining from the U.K. and the U.S., good afternoon to those in Central Europe, and good evening to those listening in Asia. Welcome, ladies and gentlemen, to AstraZeneca's Year-to-date and Q3 Results 2022 Conference Call for Investors and Analysts.

AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript

AstraZeneca (AZN) beats third-quarter estimates for earnings while sales come in line. AZN raises its 2022 earnings growth guidance, keeping its sales forecast unchanged.

AstraZeneca's (AZN) Q3 Earnings Beat, EPS Growth View Up

AstraZeneca leaned on cancer drugs in the third-quarter, leading to double-digit sales growth, a strong beat and a jump for AZN stock. The post AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth appeared first on Investor's Business Daily.

AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth

AstraZeneca PLC (NASDAQ:AZN) stock is up 7% at $65.30 at last glance, after the biotech name posted an upbeat third-quarter report and raised forecast.

AstraZeneca Stock Surges on Upbeat Earnings, Forecast

Today, TIME named AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab) on their 2022 list of Best Inventions. Their selection of EVUSHELD reflects its impact as the first and only long-acting monoclonal antibody to receive emergency use authorization in the US for the prevention of COVID-19 in immunocompromised people.

AstraZeneca EVUSHELD Named on TIME's List of the Best Inventions of 2022

Coca-Cola

These stocks both pay more than 2% per year in dividends.

Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks

Drug giant says it will no longer seek U.S. approval for the shot, citing a likely lack of demand.

AstraZeneca Drops Plan to Sell Covid-19 Vaccine in U.S.

AstraZeneca is no longer pursuing U.S. approval of its COVID-19 vaccine, Chief Executive Pascal Soriot said in a media call on Thursday.

(OFFICIAL) AstraZeneca no longer pursuing U.S. approval for COVID vaccine

AstraZeneca PLC (LSE:AZN) has increased its earnings guidance after a strong quarter during which EPS grew by 70% at constant exchange rates. The Anglo-Swedish drugs giant says it now expects 2022 core EPS to increase by the high-twenties to low-thirties percent.

AstraZeneca raises earnings guidance as profit margins improve

AstraZeneca lifts guidance after forecast-beating profit sales

AstraZeneca on Thursday topped analysts' expectations for third-quarter profit and revenue, helped by sales of its key cancer drugs, and raised its full-year adjusted earnings forecast.

AstraZeneca tops quarterly estimates buoyed by cancer drug sales

AZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and widely outperforming the general market.

AstraZeneca Q3 Preview: Can Shares Stay Strong?

On CNBC's "Options Action," Michael Khouw of Optimize Advisors said that AstraZeneca plc. (NASDAQ: AZN) traded 3.9 times its average daily put volume on Tuesday.

Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022 - AstraZeneca (NASDAQ:AZN)

AstraZeneca PLC (LSE:AZN) looks set to launch the world's first rescue medication for asthma sufferers that also reduces the underlying inflammation associated with ‘exacerbations' of the condition. A specialist panel of the US Food & Drug Administration voted 16 to one that PT027 had a beneficial impact on adults.

AstraZeneca receives backing for new rescue inhaler

WeWork

The three major U.S. equity indexes closed higher again Monday. The Dow Jones industrials ended the day up 0.13%, the S&P 500 closed 0.09% higher and the Nasdaq saw a gain of 0.25%.

Earnings Previews: AstraZeneca, Nio, WeWork

AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintaining upward pressure on the company's share price.

Most Promising Pharmaceutical Company During A Recession

AstraZeneca PLC (LSE:AZN) and Sanofi's Beyfortus (nirsevimab) immunisation has been approved in the EU for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in infants during their first RSV season.  Beyfortus is the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy or with specific health conditions, AstraZeneca said in a statement.

AstraZeneca's Beyfortus gets EU approval for RSV in infants

Pharmaceutical giant AstraZeneca has blamed “user error” for leaving a list of credentials online for more than a year that exposed access to sensitive patient data. Mossab Hussein, chief security officer at cybersecurity startup SpiderSilk, told TechCrunch that a developer left the credentials for an AstraZeneca internal server on code sharing site GitHub in 2021.

AstraZeneca password lapse exposed patient data

AstraZeneca can get a boost from the probability that it will close out its US kidney damage lawsuit in New Jersey prior to the first bellwether case in March 2023, according to Citi. The UK pharma is one of several firms embroiled in US legal action over possible damage caused by proton pump inhibitor (PPI) heartburn drugs such as Nexium, launched by Astra in the US in 2001.

News for AstraZeneca Stock (AZN)